Add to ORKGIntravesical chemo/immunotherapy is a constituent of combination treatment for bladder cancer and widely used after transurethral resection of the tumor. The goal of intravesical therapy is to reduce the risk of a recurrence and progression of the disease, by exerting a direct cytotoxic effect on malignancy. The unique properties of the bladder make it possible to constantly improve the existing local therapy options and to develop novel ones, such as intravesical electrophoresis, local hyperthermia, gene therapy, and the use of penetrants and magnetic particles. The given review combines the physicochemical and pharmacokinetic properties of drugs, the histoarchitectonic features of the bladder, the present and future of intravesical therap...
Background: In 2002 there were estimated to be 357,000 new cases of bladder cancer worldwide and 14...
Bladder cancer treatment remains a challenge despite significant improvements in preventing disease ...
International audienceSuperficial bladder cancer is treated by transuretral resection and in some ca...
Background: Tumor recurrence is the most expected clinical event after the resection of non-muscle i...
Background: Tumor recurrence is the most expected clinical event after the resection of non-muscle i...
Background: Tumor recurrence is the most expected clinical event after the resection of non-muscle i...
Background: Tumor recurrence is the most expected clinical event after the resection of non-muscle i...
Bladder cancer is the 10th most frequently diagnosed cancer worldwide with 5-year survival rate arou...
BACKGROUND: Tumor recurrence is the most expected clinical event after the resection of non-muscle ...
The management of non-muscle-invasive urothelial carcinoma of the bladder (UCB) is a challenge for p...
Transurethral resection (TUR) of the superficial transitional cell carcinoma (TCC) of the bladder is...
Non-muscle-invasive bladder cancer (NMIBC) is characterized by a tendency for recurrence and capacit...
Background: In 2002 there were estimated to be 357,000 new cases of bladder cancer worldwide and 14...
Background: In 2002 there were estimated to be 357,000 new cases of bladder cancer worldwide and 14...
Background: In 2002 there were estimated to be 357,000 new cases of bladder cancer worldwide and 14...
Background: In 2002 there were estimated to be 357,000 new cases of bladder cancer worldwide and 14...
Bladder cancer treatment remains a challenge despite significant improvements in preventing disease ...
International audienceSuperficial bladder cancer is treated by transuretral resection and in some ca...
Background: Tumor recurrence is the most expected clinical event after the resection of non-muscle i...
Background: Tumor recurrence is the most expected clinical event after the resection of non-muscle i...
Background: Tumor recurrence is the most expected clinical event after the resection of non-muscle i...
Background: Tumor recurrence is the most expected clinical event after the resection of non-muscle i...
Bladder cancer is the 10th most frequently diagnosed cancer worldwide with 5-year survival rate arou...
BACKGROUND: Tumor recurrence is the most expected clinical event after the resection of non-muscle ...
The management of non-muscle-invasive urothelial carcinoma of the bladder (UCB) is a challenge for p...
Transurethral resection (TUR) of the superficial transitional cell carcinoma (TCC) of the bladder is...
Non-muscle-invasive bladder cancer (NMIBC) is characterized by a tendency for recurrence and capacit...
Background: In 2002 there were estimated to be 357,000 new cases of bladder cancer worldwide and 14...
Background: In 2002 there were estimated to be 357,000 new cases of bladder cancer worldwide and 14...
Background: In 2002 there were estimated to be 357,000 new cases of bladder cancer worldwide and 14...
Background: In 2002 there were estimated to be 357,000 new cases of bladder cancer worldwide and 14...
Bladder cancer treatment remains a challenge despite significant improvements in preventing disease ...
International audienceSuperficial bladder cancer is treated by transuretral resection and in some ca...